International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-4 : 564-576 doi: 10.5281/zenodo.16868074
Original Article
A Study of Lipid Profile and Coronary Angiographic Profile In Young Stemi Patients
 ,
 ,
 ,
Published
Aug. 13, 2025
Abstract

Acute coronary syndrome (ACS) is the primary cause of death in developed nations and ranks among the top contributors to disease burden in developing regions as well. It is the primary cause of death in developed nations and ranks among the top contributors to disease burden in developing regions as well. The majority of participants were male (95.0%), with only 5.0% being female. Among the patients, 30.0% had a good EF, 42.5% had mild dysfunction, 22.5% had moderate dysfunction, and 5.0% had severe dysfunction. A slightly higher proportion of patients (52.5%) underwent thrombolysis (L), while 47.5% underwent primary PCI. Most participants (77.5%) were non-smokers, while 22.5% were smokers. A significant majority (85.0%) did not have diabetes, whereas 15.0% were diabetic. Hypertension was present in only 5.0% of patients, while 95.0% did not have hypertension. The prevalence of single-vessel disease (SVD) was highest in the LAD (40.0%), followed by RCA involvement (22.5%), with 2.5% having LCX involvement. Double-vessel disease (DVD) was present in 15.0% of cases, while triple-vessel disease (TVD) was found in 10.0%. A majority (82.5%) of patients did not have recanalization, whereas 17.5% showed recanalization. Although there are differences in the distribution of coronary artery disease patterns among individuals with and without dyslipidaemia, none of the observed associations reach statistical significance. This suggests that while dyslipidaemia may contribute to disease progression, its direct impact on specific vessel involvement or recanalization outcomes is not clearly established in this sample study

Recommended Articles
Loading Image...
Volume-6, Issue-4
Citations
187 Views
32 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved